Tipus de document

Article

Versió

Versió acceptada

Data de publicació

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/178408

Orally active peptide vector allows using cannabis to fight pain while avoiding side effects

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

The activation of cannabinoid CB1 receptors (CB1R) by Δ9-tetrahydrocannabinol (THC), the main component of Cannabis sativa, induces analgesia. CB1R activation, however, also causes cognitive impairment via the serotonin 5HT2A receptor (5HT2AR), a component of a CB1R−5HT2AR heteromer, posing a serious drawback for cannabinoid therapeutic use. We have shown that peptides reproducing CB1R transmembrane (TM) helices 5 and 6, fused to a cell-penetrating sequence (CPP), can alter the structure of the CB1R−5HT2AR heteromer and avert THC cognitive impairment while preserving analgesia. Here, we report the optimization of these prototypes into drug-like leads by (i) shortening the TM5, TM6, and CPP sequences, without losing the ability to disturb the CB1R−5HT2AR heteromer, and (ii) extensive sequence remodeling to achieve protease resistance and blood−brain barrier penetration. Our efforts have culminated in the identification of an ideal candidate for cannabis-based pain management, an orally active 16-residue peptide preserving THC-induced analgesia.

Matèries (anglès)

Citació

Citació

GALLO, Maria, et al. Orally active peptide vector allows using cannabis to fight pain while avoiding side effects. Journal of Medicinal Chemistry. 2021. Vol. 64, num. 10, pags. 6937-6948. ISSN 0022-2623. [consulted: 25 of May of 2026]. Available at: https://hdl.handle.net/2445/178408

Exportar metadades

JSON - METS

Compartir registre